Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Merck KGaA (MRK.DE)
Darmstadt, DE
Merck KGaA is a German science and technology company with operations divided into three core segments: Life Science, Healthcare, and Electronics. The Life Science division supplies essential tools, chemicals, and equipment to academic research institutions, biotechnology firms, pharmaceutical manufacturers, and various industrial sectors. It also offers specialized process development expertise, such as continuous bioprocessing for drug manufacturers, provides a range of testing kits, reagents, and services, and develops solutions for analyzing environmental samples like air, water, and soil. Furthermore, this segment aids in assessing nutritional value and identifying quality control issues. In its Healthcare segment, the company is involved in the entire lifecycle of prescription drugs and biopharmaceuticals, from initial discovery and development through manufacturing and marketing. Its therapeutic focus areas include oncology, neurology and immunology, fertility, endocrinology, cardiovascular diseases, diabetes, thyroid disorders, and multiple sclerosis. This segment also produces general medicines, injection devices, and software for disease monitoring. The Electronics division delivers critical materials for the semiconductor and display industries. It also specializes in surface design, providing delivery systems and services, along with a variety of surface solutions for applications such as cosmetics, effect pigments, and other functional materials. Merck KGaA is also actively engaged in strategic partnerships. These include in-licensing agreements with Debiopharm International SA for developing treatments for head and neck cancer, with Jiangsu Hengrui Pharmaceuticals Co. Ltd. for metastatic colorectal cancer drug candidates, and with Abbisko Therapeutics Co. Ltd. for therapies targeting tenosynovial giant cell tumors. Additionally, the company is involved in collaborations focused on discovering and developing targeted protein degraders against critical oncogenic proteins. Founded in 1668 and headquartered in Darmstadt, Germany, Merck KGaA operates as a subsidiary of E. Merck KG.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.82% | +4.22% | -0.97% | -7.60% | +1.38% | -3.77% | +2.04% | -26.40% | -16.86% | +42.19% | +491.18% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 8 | 0 |
| Hold | 5 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-0.3% Q1'26: -2.8% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-6.1% Q1'26: -10.1% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+12.3% Q1'26: +7.1% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+19.3% ★ Q1'26: +19.3% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+8.5% ★ Q1'26: +7.8% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q1'26: 0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×2.01× Q1'26: 2.02× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2011 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 13 Rev. Ana. 12 EPS Ana. |
Dec 2027 13 Rev. Ana. 12 EPS Ana. |
Dec 2028 11 Rev. Ana. 8 EPS Ana. |
Dec 2029 5 Rev. Ana. 6 EPS Ana. |
Dec 2030 5 Rev. Ana. 6 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
10.28B
est: 10.37B (-0.9%)
|
11.17B
est: 11.19B (-0.1%)
|
11.10B
est: 11.24B (-1.3%)
|
11.36B
est: 11.52B (-1.4%)
|
12.84B
est: 12.83B (+0.1%)
|
15.02B
est: 15.03B (0.0%)
|
14.52B
est: 15.29B (-5.1%)
|
14.84B
est: 14.77B (+0.4%)
|
16.15B
est: 16.10B (+0.3%)
|
17.53B
est: 17.42B (+0.6%)
|
19.69B
est: 19.64B (+0.2%)
|
22.23B
est: 22.25B (-0.1%)
|
20.99B
est: 20.87B (+0.6%)
|
21.16B
est: 21.13B (+0.1%)
|
21.10B
est: 21.18B (-0.4%)
|
20.96B
20.61B – 21.34B
-1.1% YoY
|
21.97B
21.28B – 22.34B
+4.8% YoY
|
23.17B
23.15B – 23.19B
+5.5% YoY
|
24.33B
23.75B – 24.76B
+5.0% YoY
|
25.47B
24.85B – 25.92B
+4.7% YoY
|
| EBITDA |
2.41B
est: 2.17B (+10.9%)
|
3.14B
est: 2.38B (+32.1%)
|
3.33B
est: 1.91B (+74.4%)
|
3.09B
est: 2.73B (+13.2%)
|
3.50B
est: 3.15B (+11.0%)
|
4.17B
est: 3.18B (+31.4%)
|
3.77B
est: 3.88B (-2.8%)
|
3.50B
est: 3.55B (-1.3%)
|
3.91B
est: 5.84B (-33.1%)
|
4.91B
est: 3.65B (+34.4%)
|
5.99B
est: 3.83B (+56.5%)
|
6.79B
est: 4.02B (+68.8%)
|
5.83B
est: 6.10B (-4.5%)
|
6.17B
est: 5.29B (+16.6%)
|
5.95B
est: 6.19B (-4.0%)
|
6.12B
6.02B – 6.24B
-1.1% YoY
|
6.42B
6.22B – 6.53B
+4.8% YoY
|
6.77B
6.76B – 6.78B
+5.5% YoY
|
7.11B
6.94B – 7.24B
+5.0% YoY
|
7.44B
7.26B – 7.57B
+4.7% YoY
|
| EBIT |
1.16B
est: 1.26B (-7.4%)
|
1.82B
est: 1.22B (+49.5%)
|
2.09B
est: 968.52M (+115.9%)
|
1.83B
est: 1.64B (+11.0%)
|
2.11B
est: 2.01B (+5.1%)
|
2.37B
est: 2.18B (+8.5%)
|
2.01B
est: 2.52B (-20.4%)
|
1.75B
est: 2.33B (-24.7%)
|
2.00B
est: 1.89B (+6.1%)
|
3.15B
est: 2.30B (+36.9%)
|
4.28B
est: 2.41B (+77.5%)
|
5.00B
est: 2.53B (+97.1%)
|
4.04B
est: 4.32B (-6.3%)
|
4.37B
est: 4.37B (-0.2%)
|
4.07B
est: 4.38B (-7.2%)
|
4.33B
4.26B – 4.41B
-1.1% YoY
|
4.54B
4.40B – 4.62B
+4.8% YoY
|
4.79B
4.79B – 4.80B
+5.5% YoY
|
5.03B
4.91B – 5.12B
+5.0% YoY
|
5.27B
5.14B – 5.36B
+4.7% YoY
|
| Net Income |
606.51M
est: 713.49M (-15.0%)
|
566.70M
est: 661.13M (-14.3%)
|
1.20B
est: 569.66M (+111.0%)
|
1.16B
est: 1.23B (-5.7%)
|
1.11B
est: 1.32B (-15.7%)
|
1.63B
est: 1.32B (+23.4%)
|
2.61B
est: 1.66B (+57.2%)
|
1.13B
est: 2.50B (-54.8%)
|
1.32B
est: 3.68B (-64.2%)
|
1.99B
est: 1.43B (+38.7%)
|
3.06B
est: 1.50B (+103.4%)
|
3.33B
est: 3.08B (+8.0%)
|
2.82B
est: 2.63B (+7.5%)
|
2.78B
est: 3.78B (-26.5%)
|
2.61B
est: 3.65B (-28.5%)
|
3.29B
3.07B – 3.52B
-9.7% YoY
|
3.66B
3.38B – 3.93B
+11.1% YoY
|
4.12B
3.64B – 4.61B
+12.7% YoY
|
4.54B
4.39B – 4.64B
+10.0% YoY
|
4.82B
4.67B – 4.93B
+6.3% YoY
|
| SGA |
3.64B
est: 3.77B (-3.5%)
|
3.65B
est: 3.87B (-5.6%)
|
3.55B
est: 3.56B (-0.4%)
|
3.48B
est: 3.53B (-1.4%)
|
4.08B
est: 3.97B (+2.6%)
|
4.34B
est: 4.72B (-8.1%)
|
4.23B
est: 4.49B (-5.6%)
|
4.40B
est: 4.07B (+8.2%)
|
4.84B
est: 4.65B (+4.2%)
|
4.49B
est: 5.08B (-11.7%)
|
4.86B
est: 5.33B (-9.0%)
|
5.26B
est: 5.60B (-6.2%)
|
5.02B
est: 5.07B (-1.1%)
|
5.16B
est: 6.21B (-16.8%)
|
5.27B
est: 5.15B (+2.2%)
|
5.10B
5.01B – 5.19B
-1.1% YoY
|
5.34B
5.17B – 5.43B
+4.8% YoY
|
5.63B
5.63B – 5.64B
+5.5% YoY
|
5.92B
5.77B – 6.02B
+5.0% YoY
|
6.19B
6.04B – 6.30B
+4.7% YoY
|
| EPS |
1.40
est: 3.57 (-60.8%)
|
1.31
est: 3.83 (-65.8%)
|
2.77
est: 4.46 (-37.9%)
|
2.66
est: 4.70 (-43.4%)
|
2.56
est: 4.89 (-47.6%)
|
3.75
est: 6.28 (-40.3%)
|
5.99
est: 6.20 (-3.4%)
|
2.60
est: 5.26 (-50.6%)
|
3.04
est: 5.53 (-45.0%)
|
4.57
est: 6.73 (-32.1%)
|
7.03
est: 8.76 (-19.7%)
|
7.65
est: 10.19 (-25.0%)
|
6.50
est: 6.04 (+7.6%)
|
6.39
est: 8.72 (-26.8%)
|
6.00
est: 8.43 (-28.8%)
|
7.80
7.07 – 8.09
-7.4% YoY
|
8.56
7.78 – 9.05
+9.7% YoY
|
9.44
8.37 – 10.60
+10.3% YoY
|
10.43
10.11 – 10.67
+10.6% YoY
|
11.09
10.74 – 11.35
+6.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-11 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-08 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-07 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-06 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-05 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-04 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-30 | B | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-15 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
No beneficial ownership filings recorded.
Institutional Activity (13F)
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | REIK & CO., LLC | 4.0K +— (+0.0%) | 590.4K +68.0K (+13.0%) | 0.00% +0.000 pp | 0.16% +0.028 pp | EUR85.04 +44.2% | 41 qtrs — |
| 2 | GAMMA INVESTING LLC | 34.00 +— (+0.0%) | 5.0K +577.0 (+13.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | EUR144.15 -14.9% | 9 qtrs — |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Belen Garijo Lopez | Executive Officer | 7M | female |
| Kai Beckmann | CEO & Chair of Management Board | 5M | — |
| Helene von Roeder | Chief Financial Officer & Member of Executive Board | 5M | female |
| Danny Pinhas Bar-Zohar | Member of the Executive Board & Chief Executive Officer of Healthcare | 1M | male |
| Khadija Ben Hammada | Member of the Executive Board & Chief People Officer | 1M | female |
| Jean Charles Wirth | Member of the Executive Board & Chief Executive Officer Life Science | 1M | male |
| Marc Horn | Head of Life Science Controlling | — | male |
| Benjamin Hein | Member of Management Board & CEO of Electronics Business Sector | — | male |
| Florian Schraeder | Head of Investor Relations | — | — |
| Frank Gotthardt | Head of Corporate & Government Relations - Europe | — | male |
| Axel Lober | Head of Global Communications | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MRK.DE
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
